Dark

Check out our Dark Pool Levels

HARP
Harpoon Therapeutics, Inc. Common Stock
stock NASDAQ

Inactive

Mar 8, 2024

23.01USD+0.087%(+0.02)6,624,340

Pre-market

0.00USD-100.000%(-22.99)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Jan 11, 2022

08:14AM EST Harpoon Therapeutics Provides Pipeline Development Milestones For 2022 Benzinga

08:00AM EST Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today provided a pipeline milestone update on its TriTAC development programs. GlobeNewswire Inc

Dec 13, 2021

04:11PM EST Harpoon Therapeutics Offers Pipeline Update For TriTAC Programs, T Cell Engager Platforms Benzinga

04:05PM EST Harpoon Therapeutics Provides Pipeline Update for GlobeNewswire Inc

Dec 11, 2021

09:11AM EST Harpoon Therapeutics Presented Interim Clinical Data from its Ongoing Phase 1/2 Study and New Preclinical Results for BCMA-targeting TriTAC HPN217 at ASH 2021; Said Encouraging Clinical Activity in Higher Dose cohorts with 63% ORR and 88% DCR Reported in 2150 g/week Cohort with 8 Disease Evaluable Patients with Relapsed/refractory Multiple Myeloma Benzinga

09:00AM EST Encouraging clinical activity in higher dose cohorts with 63% ORR and 88% DCR reported in 2150 g/week cohort with 8 disease evaluable patients with relapsed/refractory multiple myeloma GlobeNewswire Inc

Dec 7, 2021

07:30AM EST Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that it will host a conference call and webcast to review the clinical status and provide an update on its pipeline programs. GlobeNewswire Inc

Nov 12, 2021

07:20AM EST Codiak Biosciences, Kymera Therapeutics, Adicet, Celldex, Alector, Achilles, Innate, Celyad, Ruby, Replimune, Nkarta, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14 Benzinga

07:20AM EST Codiak Biosciences, Kymera Therapeutics, Adicet, Celldex, Achilles, Innate, Celyad, Ruby, Replimune, Nkarta, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14 Benzinga

07:18AM EST Codiak Biosciences, Kymera Therapeutics, Adicet, Celldex, Celyad, Ruby, Replimune, Nkarta, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14 Benzinga

07:17AM EST Codiak Biosciences, Kymera Therapeutics, Adicet, Celldex, Celyad, Ruby, Replimune, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14 Benzinga

07:16AM EST Codiak Biosciences, Kymera Therapeutics, Adicet, Celldex, Celyad, Replimune, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14 Benzinga

07:15AM EST Codiak Biosciences, Kymera Therapeutics, Adicet, Celyad, Replimune, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14 Benzinga

07:14AM EST Codiak Biosciences, Kymera Therapeutics, Adicet, Celyad, Replimune, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14 Benzinga

07:12AM EST Codiak Biosciences, Kymera Therapeutics, Adicet, Celyad, Replimune, Corvus, Harpoon, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14 Benzinga

07:00AM EST Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today presented a poster with preclinical data on its TriTAC-XR T cell engager platform at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in Washington, D.C. GlobeNewswire Inc

Nov 11, 2021

05:03AM EST SVB Leerink Maintains Outperform on Harpoon Therapeutics, Lowers Price Target to $19 Benzinga

Nov 10, 2021

05:39PM EST Harpoon Therapeutics Q3 EPS $(0.51) Up From $(0.53) YoY, Sales $4.48M Up From $3.89M YoY Benzinga

Oct 26, 2021

04:37PM EDT Harpoon Therapeutics President, CEO Jerry McMahon Resigns; Co Names Julie Eastland As President, CEO Benzinga

Oct 12, 2021

08:13AM EDT The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology Benzinga

Oct 7, 2021

08:24AM EDT The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results Benzinga

Oct 6, 2021

07:33AM EDT The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal Benzinga

Oct 5, 2021

08:01AM EDT The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout Benzinga

07:32AM EDT Harpoon Therapeutics To Present Preclinical Data On Its TriTAC-XR Platform At The 36th Annual Meeting Of The Society For Immunotherapy Of Cancer Benzinga

07:30AM EDT Harpoon Therapeutics to Present Preclinical Data on its TriTAC-XR GlobeNewswire Inc

Oct 1, 2021

07:56AM EDT The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO Benzinga

Sep 30, 2021

07:43AM EDT The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug Benzinga

Sep 28, 2021

10:11AM EDT Benzinga's Top Ratings Upgrades, Downgrades For September 28, 2021 Benzinga

04:59AM EDT Citigroup Upgrades Harpoon Therapeutics to Buy, Announces $16 Price Target Benzinga

Sep 23, 2021

07:57AM EDT The Daily Biotech Pulse: Restricted Authorization For Pfizer's COVID-19 Booster Dose, AbCellera Strikes Antibody Licensing Deal, Solid Biosciences Issues DMD Data Benzinga

05:38AM EDT Harpoon Therapeutics CEO George Erbez Reported Purchase of 10,300 Shares @ Avg Price of $8.10/Share in Form 4 Filing on Wednesday Benzinga

Sep 22, 2021

07:45AM EDT The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs Benzinga

Sep 17, 2021

07:36AM EDT The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera's COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold Benzinga

Sep 2, 2021

07:30AM EDT Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Gerald McMahon, Ph.D., President and Chief Executive Officer, will participate in three upcoming virtual investor conferences: GlobeNewswire Inc

Aug 20, 2021

07:45AM EDT The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data Benzinga

Aug 17, 2021

08:28AM EDT The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business Benzinga

Aug 13, 2021

07:43AM EDT The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO Benzinga

Aug 12, 2021

08:09AM EDT The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma Benzinga

Aug 6, 2021

05:33AM EDT SVB Leerink Maintains Outperform on Harpoon Therapeutics, Lowers Price Target to $25 Benzinga

Aug 5, 2021

05:23PM EDT Harpoon Therapeutics Q2 EPS $(0.52) Down From $(0.51) YoY, Sales $5.84M Up From $2.76M YoY Benzinga

08:08AM EDT The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO Benzinga

Aug 4, 2021

07:52AM EDT The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings Benzinga

Aug 3, 2021

04:05PM EDT Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Gerald McMahon, Ph.D., President and Chief Executive Officer, will participate in two upcoming virtual investor conferences: GlobeNewswire Inc

Jul 28, 2021

07:33AM EDT The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal Benzinga

Jul 27, 2021

11:13AM EDT The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts Benzinga

Jun 8, 2021

10:07AM EDT Benzinga's Top Ratings Upgrades, Downgrades For June 8, 2021 Benzinga

08:06AM EDT 10 Biggest Price Target Changes For Tuesday Benzinga

07:36AM EDT Citigroup Downgrades Harpoon Therapeutics to Neutral, Lowers Price Target to $16 Benzinga

Jun 7, 2021

10:02AM EDT Benzinga's Top Ratings Upgrades, Downgrades For June 7, 2021 Benzinga

09:36AM EDT Harpoon's TriTAC Programs Show Reduction in Tumor Size, Stable Disease Across Solid Tumors Benzinga

08:00AM EDT Wedbush Downgrades Harpoon Therapeutics to Neutral Benzinga

Jun 4, 2021

04:01PM EDT Harpoon Therapeutics Offers Update On TriTAC Programs, ProTriTAC Platform: 3 Programs Show Tumor Size Reductions, All 4 Programs Show Half-Life Extension Benzinga

04:00PM EDT Harpoon Therapeutics Provides Progress Update for GlobeNewswire Inc

02:43PM EDT Mid-Afternoon Market Update: Nasdaq Gains 200 Points; DocuSign Shares Jump Following Strong Q1 Results Benzinga

12:12PM EDT Mid-Day Market Update: Gold Rises Over 1%; Harpoon Therapeutics Shares Plummet Benzinga

10:44AM EDT Harpoon Therapeutics Stock Drops After Prostate Cancer Candidate Shows Cytokine-Related Adverse Events Benzinga

10:12AM EDT Mid-Morning Market Update: Markets Open Higher; US Economy Adds 559,000 Jobs in May Benzinga

09:24AM EDT Harpoon Therapeutics Presents Updated Interim Clinical Data for the PSMA-targeting TriTAC HPN424 at the 2021 ASCO Annual Meeting Benzinga

09:00AM EDT Harpoon Therapeutics Presents Updated Interim Clinical Data for GlobeNewswire Inc

May 28, 2021

10:10AM EDT Benzinga's Top Ratings Upgrades, Downgrades For May 28, 2021 Benzinga

07:52AM EDT Cantor Fitzgerald Initiates Coverage On Harpoon Therapeutics with Overweight Rating, Announces Price Target of $40 Benzinga

May 19, 2021

05:25PM EDT Pharma/Biotech Companies Highlight Upcoming Presentations At American Society Of Clinical Oncology Jun. 4-8, 2021 Benzinga

05:02PM EDT Harpoon Therapeutics to Present Updated Interim Clinical Data for GlobeNewswire Inc

May 6, 2021

04:32PM EDT Harpoon Therapeutics Q1 EPS $(1.95) Down From $(0.51) YoY, Sales $9.01M Up From $3.30M YoY Benzinga

Apr 28, 2021

04:05PM EDT Harpoon Therapeutics to Participate in Truist Securities Life GlobeNewswire Inc

Apr 26, 2021

06:22AM EDT Harpoon Therapeutics 8-K Shows Delaware Court Issues Memorandum Awarding Millennium Therapeutics $38.2M in Damages Plus Pre-Judgment Interest On Claims Against Harpoon For Fraud Benzinga

Apr 12, 2021

09:59AM EDT Harpoon Therapeutics Saturday Morning Announced Data From Poster Presentations At American Association For Cancer Research Conference Benzinga

Apr 10, 2021

08:30AM EDT Harpoon Therapeutics Announces Data from Poster Presentations at GlobeNewswire Inc

Mar 24, 2021

05:10PM EDT Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced the appointment of Alan Colowick, M.D., to its board of directors. Dr. Colowick is an experienced biotech leader and has served in numerous executive and board roles. GlobeNewswire Inc

Mar 11, 2021

01:17PM EST Harpoon Therapeutics Announces Poster Presentations At AACR Annual Meeting 2021 Apr. 10 Benzinga

01:16PM EST Harpoon Therapeutics Announces Poster Presentations and GlobeNewswire Inc

05:28AM EST SVB Leerink Maintains Outperform on Harpoon Therapeutics, Lowers Price Target to $29 Benzinga

Mar 10, 2021

04:12PM EST Harpoon Therapeutics Q4 EPS $(0.45) Beats $(0.54) Estimate, Sales $7.49M Beat $5.18M Estimate Benzinga

04:05PM EST Provided positive update on its four TriTAC clinical trials, including a confirmed partial response for HPN424 in the treatment of metastatic castration-resistant prostate cancer GlobeNewswire Inc

07:26AM EST The Daily Biotech Pulse: MediciNova Bags BARDA Contract, Lilly's COVID-19 Antibody Cocktail Data, Bluebird Bio Refutes Blood Cancer Link Benzinga

04:04AM EST Earnings Scheduled For March 10, 2021 Benzinga

Mar 9, 2021

07:30AM EST Harpoon Therapeutics to Participate in 33rd Annual Roth Conference GlobeNewswire Inc

Mar 6, 2021

10:58AM EST The Week Ahead In Biotech (March 7-13): Conference Presentations And More Earnings Benzinga

Mar 4, 2021

07:30AM EST Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that it will report fourth quarter and full year 2020 financial results and provide a corporate update on Wednesday, March 10, 2021. Harpoons management will host a webcast and conference call that day at 4:30 p.m. ET / 1:30 p.m. PT. GlobeNewswire Inc

Feb 17, 2021

07:30AM EST Harpoon Therapeutics to Participate in SVB Leerink Global GlobeNewswire Inc

Jan 20, 2021

07:32AM EST The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study Benzinga

Jan 13, 2021

02:41PM EST Harpoon Therapeutics shares were trading higher after the company announced that the FDA has granted an orphan drug designation for its HPN217 for the treatment of multiple myeloma. Benzinga

07:37AM EST Harpoon Says FDA Granted Orphan Drug Designation For HPN217 For Treatment Of Multiple Myeloma RTTNews

07:31AM EST Harpoon Therapeutics Granted Orphan Drug Designation From FDA For HPN217 For Treatment Of Multiple Myeloma Benzinga

07:30AM EST Harpoon Therapeutics Granted Orphan Drug Designation from FDA for GlobeNewswire Inc

Jan 11, 2021

04:01PM EST Harpoon Therapeutics Announces Closing of Public Offering of GlobeNewswire Inc

Jan 6, 2021

10:36PM EST Harpoon Therapeutics Prices Public Offering Of 5.88 Mln Shares At $17.00/shr RTTNews

09:44PM EST Harpoon Therapeutics Announces Pricing of Public Offering of GlobeNewswire Inc

04:30PM EST Hearing Harpoon Therapeutics Offering To Be Priced At $17/Share Benzinga

04:04PM EST Harpoon Therapeutics Reports Common Stock Offering, No Size Disclosed Benzinga

04:01PM EST Harpoon Therapeutics Announces Proposed Public Offering of Common GlobeNewswire Inc

Jan 4, 2021

07:31AM EST Harpoon Therapeutics Doses First Patient with HPN328, an Anti-DLL3 T Cell Engager for Treatment of Small Cell Lung Cancer and other DLL3-Associated Tumors Benzinga

07:30AM EST Harpoon Therapeutics Doses First Patient with HPN328, an Anti-DLL3 GlobeNewswire Inc

04:38AM EST SVB Leerink Maintains Outperform on Harpoon Therapeutics, Raises Price Target to $31 Benzinga

Dec 23, 2020

06:46AM EST HC Wainwright & Co. Assumes Harpoon Therapeutics at Buy, Announces Price Target of $31 Benzinga

Dec 8, 2020

08:04AM EST The Daily Biotech Pulse: ASH Presentations, Axsome's Positive Midstage Readout, Follow-On Offerings Benzinga

08:00AM EST HPN424 has shown confirmed partial response in treatment of metastatic castration-resistant prostate cancer in highest fixed dose cohort (160 ng/kg) of continuing Phase 1/2adose escalation trial GlobeNewswire Inc

Dec 7, 2020

04:05PM EST Harpoon Therapeutics to Host Clinical Pipeline Programs Update GlobeNewswire Inc

Nov 16, 2020

07:30AM EST Harpoon Therapeutics to Participate in the 32nd Annual Piper GlobeNewswire Inc

Nov 12, 2020

04:28PM EST Harpoon Therapeutics Highlights Presentation Of Preclinical Data For HPN601 EpCAM ProTriTAC Program At 35th SITC Annual Meeting Benzinga

Nov 9, 2020

07:30AM EST Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Gerald McMahon, Ph.D., President and Chief Executive Officer, will participate in two upcoming virtual investor conferences: GlobeNewswire Inc

Nov 5, 2020

07:30AM EST Harpoon Therapeutics Abstract for HPN601 EpCAM GlobeNewswire Inc

Nov 4, 2020

04:23PM EST Harpoon Therapeutics Q3 EPS $(0.53) Up From $(0.65) YoY, Sales $3.89M Up From $1.42M YoY Benzinga

04:05PM EST Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today reported financial results for the third quarter ended September 30, 2020 and provided a corporate update. GlobeNewswire Inc

Nov 3, 2020

07:30AM EST Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced the appointment of Omer Siddiqui as Vice President, Development Operations and Project Management. Mr. Siddiqui joins Harpoon most recently from Alector, where he served as Vice President, Head of Development Operations. GlobeNewswire Inc

Sep 9, 2020

04:05PM EDT Harpoon Therapeutics to Participate in the Cantor Virtual Global GlobeNewswire Inc

Sep 2, 2020

07:30AM EDT Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Gerald McMahon, Ph.D., President and Chief Executive Officer, will participate in two upcoming virtual investor conferences: GlobeNewswire Inc

Aug 26, 2020

07:30AM EDT Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced the appointment of Karin Ann Thacker, M.Sc., as Vice President, Regulatory Affairs and Quality Assurance. Ms. Thacker joins Harpoon from Gritstone Oncology where she most recently served as Vice President, Global Regulatory Affairs. GlobeNewswire Inc

Aug 10, 2020

07:15AM EDT Citigroup Maintains Buy on Harpoon Therapeutics, Raises Price Target to $25 Benzinga

Aug 6, 2020

08:13AM EDT Wedbush Maintains Outperform on Harpoon Therapeutics, Raises Price Target to $38 Benzinga

Aug 5, 2020

04:49PM EDT Harpoon Therapeutics Q2 EPS $(0.51) Down From $(0.49) YoY, Sales $2.76M Up From $1.06M YoY Benzinga

04:05PM EDT -- Presented positive interim Phase 1 clinical trial data for PSMA-targeting HPN424 in prostate cancer at ASCO20, supporting increased dose escalation GlobeNewswire Inc

07:30AM EDT Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Gerald McMahon, Ph.D., President and Chief Executive Officer, will participate in two upcoming virtual investor conferences: GlobeNewswire Inc

Aug 4, 2020

11:09AM EDT Insider Buys Harpoon Therapeutics's Shares Benzinga

Share